Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development
Drug Discovery
Pharmaceutical Research
Preclinical Research
Botanical Drug Preclinical R&D
02 Innovative Drug Services
ADC
PROTAC
mRNA Vaccine
Cellular Immunotherapies
Nucleic Acid Drug
Peptide Drug Conjugate (PDC)
Antibody
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection
Metabolite Identification (MetID)
Drug Forming Research
Flow Cytometry Technology
SEND Format Conversion
Flow Sorting
NanoString nCounter Detection
Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model
Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease
05 Advanced Preparation R&D
Inhalation drug
Ophthalmic drug
Skin Topical Preparation
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Campus Recruitment
Recruitment
Campus Recruitment
Campus Recruitment
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsFeatured Stories

Featured Stories

Hot information：
Top 10 Global CDMO Enterprises| The Meaning of IND, NDA and ANDA| Top 10 Global Clinical Research Organizations in 2021
Nov 29,2019
Medicilon successfully passed the proficiency test of the China Inspection Institute
Since its entry into the Sci-tech Innovation Board, Medicilon has continued to have good news. Recently, the Pharmacokinetic and Bioanalytical Department of Medicilon successfully passed the proficiency testing project organized by the China Institute for Food and Drug Control and obtained the certificate! This is the third consecutive year that the Pharmacokinetics and Bioanalysis DepartmentRead more
More
Medicilon successfully passed the proficiency test of the China Inspection Institute
Nov 18,2019
Medicilon successfully exhibited in the SAPA CT Annual Conference
Medicilon successfully exhibit in the SAPA-CT annual conference which was held in New Haven, CT on Oct 19.  Dr. Frank Wang, VP of Medicilon, attended the conference along with Dr. Cindy Chen, Dr. Lain H Cai and Sally Tang, the BDs of Medicilon. During the 1-on-1 client meetings and the booth, many companies showed interestedRead more
More
Medicilon successfully exhibited in the SAPA CT Annual Conference
Nov 08,2019
The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study
Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study, DMPK study and the safety evaluation. Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies.
More
The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study
Nov 08,2019
Progress and systematic review of consistency evaluation of generic drugs
Eight years have passed since the evaluation of the consistency of generic drugs has been carried out. The excitement, wait-and-see, loss, and rational confrontation periods of the industry have all passed away. Rethinking the issue of consistency evaluation of generic drugs requires us to think from the top-level design of the pharmaceutical industry. We lookRead more
More
Oct 30,2019
Medicilon assists pharmaceutical companies to successfully pass the consistency evaluation
Recently, Medicilon's CMC preparations have developed another success. Amlodipine besylate tablets, a cardiovascular drug 289 base drug project developed for customers for lowering blood pressure, has been obtained by the National Medical Products Administration (NMPA). This is one of the consistency evaluation drugs approved by Medicilon and its customers. The project lasted for nearly 3Read more
More
Oct 08,2019
Medicilon will participate SAPA-CT Annual Conference 2019
The SAPA-CT Annual Conference will take place in New Haven, CT on Oct 19, 2019.  Sino-American Pharmaceutical Professionals Association (SAPA) was founded in 1993 and grew rapidly and has become one of the most active and well-recognized Chinese-heritage enduring professional organizations in the United States. SAPA is an independent, nonprofit and professional organization with over 4,000Read more
More
Medicilon will participate SAPA-CT Annual Conference 2019
Sep 29,2019
AI - Assist in the Drug Development Process
Artificial intelligence technology (AI) technology can improve R & D efficiency to a certain extent and reduce cost investment. With the rise of artificial intelligence waves, drug research and development staff will quickly use these new tools to arm themselves to improve the efficiency of drug research and development. New drugs' design, discovery, and research and development process will also be shortened.
More
AI - Assist in the Drug Development Process
Sep 21,2019
The Development of the Pharmaceutical CRO Market
On a global scale, the pharmaceutical industry is facing tremendous pressure to control costs, because all large pharmaceutical companies are currently reducing their internal capabilities in manufacturing, R&D, and marketing, and costs are mainly turned to outsourcing. CRO has become an indispensable part of every pharmaceutical company because they often rely heavily on outsourcing servicesRead more
More
The Development of the Pharmaceutical CRO Market
Aug 26,2019
The Fifth Advanced Training Course for Drug Non-clinical Safety Evaluation
On August 16-19, 2019, sponsored by the Chinese Pharmaceutical Association Drug Safety Evaluation and Research Committee, China Food and Drug Control Research Institute, Shanghai Medicilon (referred to as "Medicine”) sponsored the "No. 5 The "Advanced Training Course for Persons in Charge of Non-clinical Safety Evaluation of Drugs” successfully concluded in Shanghai. The training course lastedRead more
More
The Fifth Advanced Training Course for Drug Non-clinical Safety Evaluation
Aug 10,2019
Based on Zhangjiang, Medicilon helps advance drug preclinical research and development
On August 2, 2019, Medicilon's 15th Anniversary Tour Forum-Preclinical Research Symposium was held in Pudong International Talent Harbor. Medical R&D colleagues from nearly 100 enterprises participated in the conference. This seminar was sponsored by Shanghai Medicilon Biopharmaceutical Co., Ltd., and co-organized by Pudong International Talent Development Center and Shanghai Pudong New Area Bioindustry Industry Association.Read more
More
Based on Zhangjiang, Medicilon helps advance drug preclinical research and development
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->